Researchers at Kyushu University have designed a class of molecules whose ability to amplify light energy can be actively ...

Advances diabetes and obesity programs with icovamenib demonstrating durable 52-Week Phase II data and with BMF-650, Biomea’s next-generation, ...

Tested in animal models of acute myeloid leukemia, the new nanomedicine was dramatically more effective while also less toxic ...

Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for other ...

And three: what do you think of Augustinus Bader skincare? Our answer to question three is that most Augustinus Bader's ...

Palm oil comes packed with nature’s own bioactive toolkit. Among its standout features are tocotrienols, a rare and potent ...

Cash and Cash Equivalents: As of September 30, 2025, Kymera had $978.7 million in cash, cash equivalents and investments. Kymera expects that its cash balance will provide the Company with a cash ...

The FDA-approved drug Pluvicto offers hope for advanced prostate cancer patients, but access barriers remain despite proven ...

Detailed price information for Theralase Technologies Inc (TLTFF) from The Globe and Mail including charting and trades.

Lausanne, Switzerland, November 4, 2025 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today reported ...

MIT engineers have developed a flexible drug-delivery patch that can be placed on the heart after a heart attack to help ...